United Therapeutics Rated Buy as Tyvaso DPI Growth and FDA Catalysts Loom
United Therapeutics is rated Buy with a base-case valuation of $535 per share despite two consecutive quarters of revenue declines tied to competition from Liquidia's Yutrepia. The thesis says Tyvaso DPI remains the key growth product, while weakness is isolated to older formulations. Upcoming FDA reviews for IPF and Ralinepag, along with litigation outcomes and quarterly Tyvaso DPI growth, are cited as important catalysts and monitoring points.
United Therapeutics has drawn a Buy rating with a $535 base-case value even after two straight quarters of falling revenue. The stock sits about 19% below its 52-week peak of $609.35. The cited pressure comes from Liquidia’s Yutrepia, but the analyst argues the damage is confined to legacy formulations rather than the main dry-powder business.
Tyvaso DPI is described as the company’s biggest product and still expanding, making it central to the thesis. Future FDA decisions on IPF and Ralinepag, plus litigation results and quarterly Tyvaso DPI trends, are listed as key catalysts. The author would buy more aggressively under $450.
Developments at United Therapeutics may matter most to patients with pulmonary conditions, including those who could benefit from Tyvaso DPI or potential IPF and Ralinepag approvals. Competition and litigation outcomes could shape availability, pricing, and treatment choices, while investors and employees may see share-price effects. If FDA reviews succeed, more options or label expansions could reach clinicians and patients; if not, access may remain narrower. Broader market sentiment around biotech risk and drug competition may also be influenced.